Patofysiologiin í lungnakrabba vísir til broytingar í teimum vanligu fysiologisku prosessunum og mekanismunum, sum koma fyri í menningini og framgongdini av lungnakrabba.
Lungnakrabba er ein kompleks sjúka, sum stendst av óstýrdari vøkstri og býti av óvanligum kyknum í lungunum.
Hesar kyknur kunnu gera svull og spreiða seg til onnur kropslutir, og tað kann hava ymisk sjúkueyðkenni og trupulleikar við sær.
Patofysiologiin av lungnakrabba hevur fleiri faktorar við sær, eitt nú genetiskar mutatiónir, umhvørvisfaktorar og lívsstílsval.
Genetiskar mutatiónir kunnu koma fyri í DNA'inum í lungakyknunum, sum førir til óstýrdari vøkstur og býti av kyknum.
Hesar broytingar kunnu vera arvaligar ella tilkomnar, og tær kunnu standast av, at ein er útsettur fyri krabbameinsvaldandi evnum, sum til dømis tubbaksroyki, radon, asbest og luftdálking.
Lungnakrabba kann býtast í tvey høvuðssløg: smáfrumukrabba (SCLC) og ikki-smáfrumukrabba (NSCLC).
Patofysiologiin hjá hesum sløgum av lungnakrabba kann vera ymisk, tí tey hava ymiskar genetiskar mutatiónir og svara ymiskt til viðgerð.
Patofysiologiin í lungnakrabba hevur eisini samband við samspælið millum krabbameinsfrumur og umhvørvisvevnaðin, eisini immunverjuna.
Krabbameinsfrumur kunnu sleppa undan immunverjuni, og tí vaksa og breiða seg tær ótarnaðar.
Harafturat kann tumorskaðaumhvørvið fremja vøkstur og metastasur við at geva stuðul til krabbameinssellurnar.
Patofysiologiin av lungnakrabba er ein kompleks og dynamisk gongd, og granskarar arbeiða støðugt við at skilja betur teir undirliggjandi mekanismurnar fyri at menna effektivari viðgerðir og betra um úrslitini fyri sjúklingarnar.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Avsakan: sjúkuviðurskifti']
['Henda heimasíðan er bert til undirvísingar og kunningar og er ikki ætlað sum læknalig ráðgeving ella faklig tænasta.']
['Upplýsingarnar eiga ikki at verða nýttar til at staðfesta ella viðgera nakran heilsutrupulleika ella sjúku, og tey, sum ynskja persónliga læknahjálp, eiga at venda sær til ein autoriseraðan lækna.']
['Gev gætur, at tað neuronala netið, sum gevur svar uppá spurningarnar, er serliga skeivt, tá ið talan er um talgilda innihaldið, t.d. talið av fólki, sum hava fingið staðfest eina ávísa sjúku.']
['Spyr altíð læknan ella annan skikkaðan heilsuhjálpara um ráðgeving í sambandi við sjúku. Vanvirð ongantíð professionella læknaráðgeving ella drála við at leita eftir henni vegna okkurt, tú hevur lisið á hesi heimasíðu.']
['Avsakan: upphavsrættur']
['Digital Millennium Copyright Act frá 1998, 17 U.S.C. § 512 (DMCA) gevur rætt til at kæra til rættindahavarar, sum halda, at tilfar, sum kemur á internetið, brýtur teirra rættindi sambært amerikanskum lógum um upphavsrætt. ']
['Um tú í góðari trúgv heldur, at eitthvørt innihald ella tilfar, sum er gjørt tøkt í sambandi við okkara heimasíðu ella tænastur, brýtur tíni upphavsrættindi, kanst tú (ella tín umboðsmaður) senda okkum eina fráboðan, har tú biður um, at innihaldið ella tilfarið verður tikið burtur ella atgongdin til tað verður sperrað.']
['Tilmeldingarnar skulu verða skrivligar við telduposti (sí "Kontakt" fyri teldupostadressu).']
['DMCA krevur, at fráboðan um meint brot á upphavsrættin skal innihalda hesar upplýsingar: (1) lýsing av tí upphavsrættarliga verkinum, sum talan er um, (2) lýsing av tí meinta brot á upphavsrættin og upplýsingar, sum eru nøktandi til at vit kunnu finna innihaldið (3) upplýsingar um teg, t.d. tín bústað, telefonnummar og teldupostbústað (4) eina váttan frá tær um, at tú í góðari trúgv heldur, at innihaldið, sum tú klagar um, ikki er loyvt av rættindahavanum ella umboði hansara ella sambært lóggávu']
['5) eina váttan frá tær, undirskrivað undir revsing fyri lygi, um, at upplýsingarnar í fráboðanini eru rættar, og at tú hevur heimild at gera galdandi upphavsrættin, sum verður hildin at vera brotin,']
['og 6) fysiska ella elektroniska undirskrift hjá rættindahavara ella persóni, sum hevur loyvi at virka fyri rættindahavara.']
['Um tú ikki hevur upplýst allar omanfyri nevndu upplýsingar, kann tað hava við sær, at viðgerðin av klaguni verður seinkað.']
['Set teg í samband við']
['Vinarliga send okkum ein teldupost við einum hvørjum spurningi/uppskoti.']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Umleið']
['BioMedLib nýtir sjálvvirkandi teldur (maskinlæringaralgoritmur) til at gera spurningar og svar.']
['Vit byrja við 35 milliónum av biomedicinskum útgávum frá PubMed/Medline. eisini heimasíðum frá RefinedWeb.']
